Literature DB >> 10705154

What is the definition of cure for aplastic anemia?

B M Camitta1.   

Abstract

Treatment with immune suppression and bone marrow transplantation has improved the response rates and survival of patients with aplastic anemia. Measurement of response requires that common endpoints be recorded at specific times. There has been no agreement on such parameters for patients with aplastic anemia. In this paper issues related to measurement of response are reviewed and criteria for response are proposed. Adoption of uniform criteria would facilitate comparisons of treatment efficacy. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh：

Year:  2000        PMID： 10705154     DOI： 10.1159/000040999

Source DB:  PubMed          Journal:  Acta Haematol        ISSN： 0001-5792            Impact factor:   2.195


  20 in total

1.  Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia.

Authors:  Tatsuhiro Sakamoto; Naoshi Obara; Naoki Kurita; Mamiko Sakata-Yanagimoto; Hidekazu Nishikii; Yasuhisa Yokoyama; Kazumi Suzukawa; Yuichi Hasegawa; Shigeru Chiba
Journal:  Int J Hematol       Date:  2013-08-21       Impact factor: 2.490

2.  Outcome of Cyclosporine Monotherapy in Patients of Aplastic Anemia: Experience of a Tertiary Care Hospital in Eastern India.

Authors:  Prakas Kumar Mandal; Suvraneel Baul; Tuphan Kanti Dolai; Rajib De; Prantar Chakrabarti
Journal:  Indian J Hematol Blood Transfus       Date:  2016-07-19       Impact factor: 0.900

3.  Feasibility and eligibility of retreatment with rabbit anti-T lymphocyte globulin for aplastic anemia previously treated with horse anti-thymocyte globulin.

Authors:  Katsuhiro Miura; Yoshihiro Hatta; Sumiko Kobayashi; Yoshinori Iriyama; Kazuhiro Takei; Jin Takeuchi
Journal:  Int J Hematol       Date:  2009-08-29       Impact factor: 2.490

4.  Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia.

Authors:  Mahmoud I Elbadry; Hiroki Mizumaki; Kohei Hosokawa; J Luis Espinoza; Noriharu Nakagawa; Kazuhisa Chonabayashi; Yoshinori Yoshida; Takamasa Katagiri; Kazuyoshi Hosomichi; Yoshitaka Zaimoku; Tatsuya Imi; Mai Anh Thi Nguyen; Youichi Fujii; Atsushi Tajima; Seishi Ogawa; Katsuto Takenaka; Koichi Akashi; Shinji Nakao
Journal:  Haematologica       Date:  2019-03-19       Impact factor: 9.941

5.  Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia.

Authors:  Xiaotian Xie; Huijun Zhao; Dawei Qin; Xiaohong Qiao
Journal:  Int J Clin Exp Med       Date:  2015-03-15

6.  Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine.

Authors:  Yang Lan; Lixian Chang; Meihui Yi; Yuli Cai; Jing Feng; Yuanyuan Ren; Chao Liu; Xiaoyan Chen; Shuchun Wang; Ye Guo; Aoli Zhang; Lipeng Liu; Jingliao Zhang; Xiaofan Zhu
Journal:  Ann Hematol       Date:  2020-10-08       Impact factor: 3.673

7.  Evaluation of Bone Marrow Microvessel Density in Patients with Aplastic Anemia.

Authors:  Venkatesan Somasundaram; Manvir Singh Tevatia; Abhishek Purohit; Ankur Ahuja; Manoranjan Mahapatra; Seema Tyagi; Haraprasad Pati; Renu Saxena
Journal:  Indian J Hematol Blood Transfus       Date:  2016-07-19       Impact factor: 0.900

Review 8.  Clinical significance of a small population of paroxysmal nocturnal hemoglobinuria-type cells in the management of bone marrow failure.

Authors:  Shinji Nakao; Chiharu Sugimori; Hirohito Yamazaki
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490

9.  Hematologic responses in patients with aplastic anemia treated with deferasirox: a post hoc analysis from the EPIC study.

Authors:  Jong Wook Lee; Sung-Soo Yoon; Zhi Xiang Shen; Arnold Ganser; Hui-Chi Hsu; Ali El-Ali; Dany Habr; Nicolas Martin; John B Porter
Journal:  Haematologica       Date:  2013-04-12       Impact factor: 9.941

10.  Cyclosporine therapy for acquired aplastic anemia: predictive factors for the response and long-term prognosis.

Authors:  Hirohito Yamazaki; Chiharu Sugimori; Tatsuya Chuhjo; Shinji Nakao
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.